🔗 Share this article

While America proceeds with sweeping adjustments to its immunization guidelines, a particular individual appears somewhat surprisingly: Tracy Beth Høeg, an American of Danish descent sports physician and public health researcher who initially gained attention by expressing skepticism about coronavirus vaccines during the pandemic and has zeroed in on possible deaths after COVID-19 immunization in her short time at the US Food and Drug Administration (FDA).

Planned Overhauls to Childhood Vaccine Schedule

Health officials were set to announce radical changes to the childhood vaccination calendar in December, bringing the US with the Danish national calendar, sources say – a significant shift that would place the US out of alignment with a large portion of the international standard with no evidence for improved outcomes. The planned update has been postponed until the coming year.

In place of the top vaccines chief, Høeg is listed to speak at the meeting. She was recently named interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to run the office this year.

A Shift at the Regulatory Body

The acting appointment may indicate a strengthened alliance between the drug and vaccine centers as Høeg and Dr. Prasad strengthen their influence at the FDA – and it signals a increased emphasis upon reevaluating long-standing immunizations at the FDA.

Dr. Høeg has frequently advocated for discontinuing specific childhood immunization guidelines in the US to become more like the Danish model, a nation with comprehensive healthcare and a citizenry roughly the population of Wisconsin’s.

So far public appearances, she has kept her attention on immunizations – usually the purview of Dr. Prasad, chief of the FDA’s vaccine center – rather than drug regulation.

Questions Over Qualifications

Høeg has little discernible experience in drug development, oversight or administrative roles, which has been customary for former leaders of the biologics center. She has worked at the FDA as a top consultant to the agency head and CBER since earlier this year.

“She appears not to have any of the qualifications” for running the pharmaceutical oversight division, said Jonathan Howard. “She lacks experience running a clinical trial. She has no expertise in running a large organization. She lacks background in pharmaceutical oversight.”

Past commissioners of CBER would “be deeply familiar with legal statutes and the research of drug development”, noted Dr. Janet Woodcock. “Clearly, she doesn’t have the kind of background that former directors who ran the center have had.”

The drug center has an vast portfolio at the FDA, the former commissioner emphasized.

“Everybody just focuses on the innovative therapies, but the generic drug division authorizes a multitude of generic drugs. There is also a biologic copycat branch, over-the-counter program and more, and every single one must be managed,” Dr. Woodcock noted. “The area you overlook, that is precisely what that I always told people is going to bite you.”

Furthermore, a substantial leadership component to the role, which manages more than 5,000 personnel. “It’s a enormous management job, if you execute it properly,” she concluded.

Response and Contentious Initiatives

In response to concerns about Dr. Høeg's credentials and whether this selection indicates more teamwork among regulatory chiefs on vaccines, a representative responded that the “inquiries are based on incorrect assumptions”.

“Her resume aligns with the functions of her job,” the official said, noting the months Høeg spent guiding the FDA commissioner on “medication safety and regulatory science, including computerized risk analysis and immunization monitoring”.

As acting director, Høeg takes over the agency head's new expedited review system, a disputed one-day therapy clearance system that apparently concerned her predecessors. “How are these drugs being chosen for this expedited pathway? Who makes the decisions?” Howard said. “There is a lot of lack of transparency happening at the regulatory body right now.”

Overall, he stated, “the FDA seems to be moving towards more relaxed oversight of most medications, except for shots.”

Public Track Record on Vaccines

With vaccines, Dr. Høeg has a clearer, if concerning, track record, critics have noted. She published a analysis using non-validated crowd-sourced reports to determine the rate of heart inflammation after Covid vaccination. She counseled the state of Florida surgeon general Dr. Joseph Ladapo, who was said to have altered data to indicate COVID-19 vaccines are more dangerous than they are.

Among her “wish list” for the new administration included altering rules for novel immunizations and ending “unnecessary” vaccines, she remarked post-election on a podcast. At the agency, Dr. Høeg has according to sources suggested preventing adolescent males from obtaining COVID-19 vaccinations.

“She is an complete ideologue who starts off with her beliefs and tailors the evidence to retrofit the science in a very deceptive, fraudulent manner,” Howard stated.

Gaining Influence and a “Push for Payback”

Dr. Høeg became part of other skeptics, {like|